Page last updated: 2024-09-03

gefitinib and glucagon-like peptide 2

gefitinib has been researched along with glucagon-like peptide 2 in 1 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (glucagon-like peptide 2)	Trials (glucagon-like peptide 2)	Recent Studies (post-2010) (glucagon-like peptide 2)
5,231	566	2,919	798	64	442

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS	1

Other Studies

1 other study(ies) available for gefitinib and glucagon-like peptide 2

Article	Year
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-01, Volume: 13, Issue:17 Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; ErbB Receptors; Female; Gefitinib; Glucagon-Like Peptide 2; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Quinazolines	2007

Article

Year

The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-01, Volume: 13, Issue:17

Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; ErbB Receptors; Female; Gefitinib; Glucagon-Like Peptide 2; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Quinazolines

2007